A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

  • STATUS
    Recruiting
  • End date
    May 3, 2024
  • participants needed
    140
  • sponsor
    Incyte Corporation
Send
Updated on 28 October 2022
See if I qualify

Summary

The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.

Details
Condition Prurigo Nodularis
Treatment Placebo, INCB054707
Clinical Study IdentifierNCT05061693
SponsorIncyte Corporation
Last Modified on28 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Clinical diagnosis of PN for at least 3 months before screening
Inadequate response or intolerant to ongoing or prior PN therapy
≥ 20 nodules on ≥ 2 different body regions at screening and Day 1
Willingness to avoid pregnancy or fathering children
Further inclusion criteria apply

Exclusion Criteria

Have chronic pruritus due to a condition other than PN; have neuropathic and psychogenic pruritus such as but not limited to notalgia paresthetica, brachioradial pruritus, small fiber neuropathy, skin picking syndrome, or delusional parasitosis
Current use of a medication known to cause pruritus
Women who are pregnant (or who are considering pregnancy) or lactating
Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis
Participants known to be infected with HIV, Hepatitis B, or Hepatitis C
Laboratory values outside of the protocol-defined ranges
Further exclusion criteria apply
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note